Hepatitis B vaccine recombinant - VBI Vaccines

Drug Profile

Hepatitis B vaccine recombinant - VBI Vaccines

Alternative Names: Bio-Hep-B; Hepimmune; Sci-B-Vac

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer VBI Vaccines
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 07 Feb 2017 VBI Vaccines plans a pivotal clinical trial for Hepatitis B in Europe
  • 21 Sep 2016 Early research in Hepatitis B in European Union, USA (IM) before September 2016
  • 21 Sep 2016 Launched for Hepatitis B in Senegal, Nigeria, Niger, Moldova, Ivory Coast, Ghana, Georgia, Gabon, Equatorial Guinea, Chile, Central Africa (IM) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top